Press Room
News & Events
Date
Title

 
Sept 26, 2011
Neumedicines Wins U.S. Federal Government Contract for up to $273 Million to Fund Late-Stage Development of HemaMax(TM), a Novel Radiation Medical Countermeasure

 
June 8, 2011
Neumedicines Initiates Dosing in a First-in-Human Study of HemaMax™, its Novel Radiation Medical Countermeasure

 
June 6, 2011
Neumedicines’ Oncology and Hematology Drug Candidates Featured in BIOWORLD Magazine

 
Jan 27, 2011
Neumedicines Receives Notice of Allowance for Patent Covering Use of HemaMax™ (rHuIL-12) to Treat Chemotherapy-Induced Thrombocytopenia (CIT)

 
Jan 5, 2011
Neumedicines to Present at the 2011 Biotech Showcase™ Tuesday, January 11, 2011

 
Aug 12, 2010
Neumedicines Receives $2.5 Million from HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax™ as a Radiation Countermeasure

 
Oct 1, 2009
Neumedicines Receives Approximately $5 Million from HHS/BARDA in Research and Development Funding

 
Sept 16, 2008
Neumedicines Awarded BAA-BARDA-08-08 Contract by the Biomedical Research and Development Authority (BARDA)

Neumedicines in the News
 
Date
Title

 
Jun 6, 2011
"Neumedicines Gives New Life to Failed Biologic," BioWorld Today

 
April 19, 2011
"Japan Serves as Textbook for BARDA and Biotechs," BioWorld Today

 
Dec 12, 2009
"Bringing New Blood to the Anemia Market," Start-Up Magazine

 
Dec 1, 2009
"Start-Up Previews," IN VIVO Magazine

Follow Us @Neumedicines
Corporate news, events and interests
Media Contact
Jeff Richardson
p: 805.491.8313 | e: jeff@richardsonglobalpr.com